Yvonne Chu, MD
Ophthalmology · Houston, TXNPI 1033108410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,414 and has fallen 57.8% since, to $1,862 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $94.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$3K
- AbbVie$3K
- Alcon$2K
- Glaukos Corporation$2K
- Optos, Inc.$827
- Aerie Pharmaceuticals, Inc.$822
- plus $3K from 9 others
What the payments were for
- Food & beverage$13,84295%
- Entertainment$6775%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 30 | $3,371 |
| AbbVie(2 entities) | 37 | $3,010 |
| Alcon | 26 | $2,113 |
| Glaukos Corporation | 12 | $1,753 |
| Optos, Inc. | 5 | $827 |
| Aerie Pharmaceuticals, Inc. | 8 | $822 |
| Ivantis, Inc | 7 | $771 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $705 |
| Iridex Corporation | 3 | $344 |
| Sight Sciences, Inc. | 2 | $246 |
| Carl Zeiss Meditec, Inc. | 3 | $217 |
| Bausch & Lomb Americas Inc. | 2 | $129 |
| Alimera Sciences, Inc. | 1 | $113 |
| GSK | 3 | $53 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$2,131
- Kahook Dual Blade$2,131
- XEN GLAUCOMA TREATMENT SYSTEM$1,260
- Hydrus Microstent$1,119
- Clearpath$961
- Streamline$961
- Via360$833
- P200DTx$769
- P200T$769
- P200TE$769
- P200TxE$769
- Rocklatan$505
- Rhopressa$503
- iStent inject W$428
- Streamline Surgical System$392
- iStent inject Trabecular Micro-Bypass Stent System$388
- Photrexa$263
- LUMIGAN$247
- Hydrus$240
- iStent Infinite$171
How this compares
$14,519 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.